Q&A: A biotech VC leader shares her next big bets
Kristina Burow, managing director at ARCH Venture Partners and a member of the 2024 #STATUSList, spoke with STAT about her next big bets.
Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol.
Burow is a managing director at ARCH, where she has been influential in building bold and well-capitalized startups. Some of her latest are the genetic medicines startup Orbital Therapeutics and Neumora Therapeutics, which is part of a small group of startups hoping to make strides in treating psychiatric diseases. Neumora was one of the few biotechs to go public through an IPO last year. Burow also sits on the boards of several emerging biotech companies, helping to steer how they stress-test their science and what types of therapies to pursue.
What's Your Reaction?
